CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 16, 2013
Result type: Reports
Project Number: SR0364-000
Product Line: Reimbursement Review

Generic Name: Macitentan

Brand Name: Opsumit

Manufacturer: Actelion Pharmaceuticals Canada Inc.

Therapeutic Area: Pulmonary arterial hypertension

Indications: Pulmonary arterial hypertension

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 28, 2015

Recommendation Type: List with clinical criteria and/or conditions